<DOC>
	<DOCNO>NCT02227264</DOCNO>
	<brief_summary>Patients primary hyperparathyroidism ( pHPT ) often present fatigue , psychological cognitive symptom . Improvement symptom parathyroid adenomectomy ( PTX ) report . But physicians lack method attribute symptom pHPT predict reversibility PTX . This study aim evaluate short-term calcimimetic treatment tool predict outcome PTX muscle strength , quality life , psychological symptom , cognitive function patient pHPT . Material Methods : 118 patient schedule PTX Karolinska University Hospital , Sweden , four week treatment calcimimetics ( Mimpara® ) undergo surgery . Biochemicals , muscle strength , quality life , psychological symptom cognitive function analyse baseline , four week follow-up postoperatively . Hypothesis : The outcome short-term calcimimetic treatment predict outcome PTX muscle strength , quality life , psychological symptom , cognitive function patient pHPT</brief_summary>
	<brief_title>Primary Hyperparathyroidism : Short-term Calcimimetics Treatment - Relevance Parathyroid Surgery Decisions ?</brief_title>
	<detailed_description>The study evaluate short-term treatment calcimimetics may use patient PHPT relevant guide decision choose parathyroid surgery , predict outcome surgical treatment . 120 ± 2 patient primary hyperparathyroidism schedule parathyroid surgery include study inform consent receive study medication cinacalcet , Mimpara® 30 mgx1 four week . In case persistent hypercalcemia two week treatment Mimpara® 30 mgx1 , dosage Mimpara® increase 60 mg daily . During study drug treatment period , patient follow closely least week clinical monitoring control serum ionized calcium , give risk side effect hypocalcemia . If concentration ionize calcium serum decrease subnormal level ( &lt; 1.15 mmol/l ) , Mimpara® treatment discontinue temporarily reinserted low dose ( 30 mg x 1 ) concentration ionize calcium raise 1.33 mmol/l . The size cohort decide power estimation base result study part A . Both group go test panel self-rating scale describe four occasion ( Figure ) . The Outcome register change baseline end study medication period compare change postoperatively , thus change Visit 2 Visit 6 change Visit 2 Visit 7 Visit 8 respektively . Assessments Procedures Visit 1 : Clinical examination ( general condition , neck , blood pressure , cor et pulm ) . Screening patient primary hyperparathyroidism schedule parathyroid surgery . Patient fulfill inclusion exclusion criterion ask participate study . Visit 2 : Informed consent sign . Test panel self rating scale ( Quality Life Questionnaire-Core 30 ( QLQ-C30 ) , Positive States Mind ( PSOM ) Hospital Anxiety Depression scale ( HAD ) , cognitive test ( Montreal cognitive assessment ( MoCA-Test ) ) muscle strength ( Timed stand test ) . Blood sample draw within 2 week analyze : parathyroid hormone ( p-PTH ) , s-ionized calcium , p-total calcium , p-albumin , p-creatinine , p-phosphate , s-25-OH-D-vitamin p-TSH . Initiation treatment Mimpara® 30 mg x 1 . Clinical examination ( general condition , blood pressure ) . For fertile woman , pregnancy test demand enrollment . Visit 3 : Week 1 ( ± 2 day ) ; blood sample analysis ionized calcium . History symptom relate hypocalcemia ( paresthesias , cramp , muscle fatigue ) . Clinical examination indicate ( general condition , blood pressure ) . Visit 4 : Week 2 ( ± 2 day ) ; blood sample analysis ionized calcium . History . Mimpara® continue , If ionize calcium level &gt; 1.33 mmol/l : increase dosage Mimpara® 30 mg x 2 . Visit 5 : Week 3 ( ± 2 day ) ; blood sample analysis ionized calcium . History . Mimpara® treatment complete . Visit 6 ( 3 ) : Week 4 ( ± 2 week study B ) ; Test panel self rating scale ( QLQ-C30 , PSOM HAD ) , cognitive test ( MoCA-Test ) muscle strength ( Timed stand test ) . Blood sample draw analyze : plasma ( p ) -PTH , serum ( ) -ionized serum calcium , p-total calcium , p-albumin , p-creatinine , p-phosphate . Visit 7 ( 4 ) : Postoperative follow , 6 ( ± 1 week ) post surgery ; Test panel self rating scale ( QLQ-C30 , PSOM HAD ) , cognitive test ( MoCA-Test ) muscle strength ( Timed stand test ) . Blood sample draw analyze plasma p-PTH , s-ionized calcium , p-total calcium , p-albumin , p-creatinine , p-phosphate , s-25-OH-D-vitamin p-TSH . Visit 8 ( 5 ) : Postoperatively , 6 month post surgery ( ± 3 week ) ; Test panel self rating scale ( QLQ-C30 , PSOM HAD ) , cognitive test ( MoCA-Test ) muscle strength ( Timed stand test ) . Blood sample draw analyze plasma ( p ) -PTH , s-ionized calcium , p-total calcium , p-albumin , p-creatinine , p-phosphate , s-25-OH-D-vitamin p-TSH .</detailed_description>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Primary</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>Primary hyperparathyroidism Scheduled parathyroid surgery Age &gt; 40 Ability participate test include study model Signed consent Pregnancy Breast feed Fertile woman use contraceptive ( IUD pill ) Impaired kidney function , GFR &lt; 40 ml/min Intolerance Mimpara® Previously treat Mimpara® Participating ongoing clinical study Epilepsy Severe hepatic impairment Hypotension Heart failure ( NYHA class 34 , symptom minimal exertion ) Medication ketoconazole ( oral ) tricyclic antidepressant</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Primary hyperparathyroidism</keyword>
	<keyword>Calcimimetic Agents</keyword>
	<keyword>Parathyroid adenomectomy</keyword>
</DOC>